Hindorff Lucia A, Heckbert Susan R, Tracy Russell, Tang Zhonghua, Psaty Bruce M, Edwards Karen L, Siscovick David S, Kronmal Richard A, Nazar-Stewart Valle
Department of Epidemiology, University of Washington, Seattle, Washington, USA.
Am J Hypertens. 2002 Dec;15(12):1050-6. doi: 10.1016/s0895-7061(02)03063-7.
The angiotensin II type 1 receptor A1166C polymorphism has been associated with increased risks of hypertension and myocardial infarction in several small studies. We examined the association between this polymorphism and new-onset hypertension, blood pressure (BP) control, and incident cardiovascular events in a large population-based cohort of older adults.
Eight hundred self-identified African Americans and 1,371 randomly selected white participants in the Cardiovascular Health Study were genotyped. The median duration of follow-up was 8.1 years.
The A1166C polymorphism was not associated with new-onset hypertension, with BP control, or with incident cardiovascular events in the overall population. In white participants, the CC genotype was associated with higher baseline systolic BP and pulse pressure, compared to the AC or AA genotype. In whites with treated hypertension at baseline, compared to the AA genotype, the CC genotype was associated with increased risks of incident congestive heart failure (hazard ratio = 2.5, 95% confidence interval [CI] 1.3-4.9) and incident ischemic stroke (hazard ratio = 2.6, 95% CI 1.1-6.0). These associations were not observed among white participants without treated hypertension, but the interaction of genotype with treated hypertension on ischemic stroke and heart failure was only marginally significant.
On the whole, in this large cohort of older adults, the A1166C polymorphism was not associated with BP control or incident cardiovascular events. The subgroup findings in treated hypertensives need to be confirmed in additional studies.
在一些小型研究中,血管紧张素II 1型受体A1166C多态性与高血压和心肌梗死风险增加有关。我们在一个以人群为基础的大型老年队列中研究了这种多态性与新发高血压、血压控制及心血管事件发生之间的关联。
对心血管健康研究中800名自我认定的非裔美国人和1371名随机选取的白人参与者进行基因分型。随访的中位时间为8.1年。
在总体人群中,A1166C多态性与新发高血压、血压控制或心血管事件发生均无关联。在白人参与者中,与AC或AA基因型相比,CC基因型与更高的基线收缩压和脉压相关。在基线时患有高血压且接受治疗的白人中,与AA基因型相比,CC基因型与发生充血性心力衰竭(风险比=2.5,95%置信区间[CI] 1.3-4.9)和缺血性卒中(风险比=2.6,95% CI 1.1-6.0)的风险增加相关。在未接受治疗的高血压白人参与者中未观察到这些关联,但基因型与治疗高血压对缺血性卒中和心力衰竭的相互作用仅具有边缘显著性。
总体而言,在这个大型老年队列中,A1166C多态性与血压控制或心血管事件发生无关。治疗高血压患者的亚组研究结果需要在更多研究中得到证实。